Pfizer
Stock Forecast, Prediction & Price Target
Pfizer (PFE) stock Price Target by analysts
Pfizer (PFE) stock Price Target by analysts
Average Price Target
$32.25
Potential upside: 27.57%
Pfizer price prediction
What is Pfizer stock analysts` prediction?
Pfizer stock forecast: Based on 4 Wall Street analysts` predicted price targets for Pfizer in the last 3 months, the avarage price target is $32.25, with a high forecast of $NaN. The average price target represents a 27.57% change from the last price of $25.28.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Pfizer stock Price Target by analysts
Full breakdown of analysts given Pfizer price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Robyn Karnauskas Truist Financial | 0% 0/1 | 9 months ago | $32 26.58% upside | $25.89 | TheFly | Previous targets (0) |
Chris Shibutani Goldman Sachs | 25% 1/4 | 11 months ago | $33 30.53% upside | $28.46 | StreetInsider | Previous targets (3) |
Courtney Breen Bernstein | 0% 0/1 | 11 months ago | $32 26.58% upside | $29.67 | TheFly | Previous targets (0) |
Carter Gould Barclays | 33.33% 1/3 | 12 months ago | $32 26.58% upside | $28.93 | TheFly | Previous targets (2) |
Narumi Nakagiri Daiwa | 0% 0/1 | about 1 year ago | $34 34.49% upside | $28.85 | StreetInsider | Previous targets (0) |
Chris Shibutani Goldman Sachs | 25% 1/4 | about 1 year ago | $34 34.49% upside | $31.39 | StreetInsider | Previous targets (3) |
Mohit Bansal Wells Fargo | 0% 0/3 | about 1 year ago | $30 18.67% upside | $31.39 | TheFly | Previous targets (2) |
Vamil Divan Guggenheim | 0% 0/1 | about 1 year ago | $36 42.40% upside | $30.72 | Benzinga | Previous targets (0) |
Carter Gould Barclays | 33.33% 1/3 | about 1 year ago | $30 18.67% upside | $27.72 | TheFly | Previous targets (2) |
Evan Seigerman BMO Capital | 0% 0/2 | over 1 year ago | $36 42.40% upside | $29.6 | TheFly | Previous targets (1) |
Louise Chen Cantor Fitzgerald | 0% 0/2 | over 1 year ago | $45 78.00% upside | $26.97 | Benzinga | Previous targets (1) |
Thomas Yeh Morgan Stanley | 100% 1/1 | over 1 year ago | $20 -20.88% downside | $26.93 | Benzinga | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/1 | almost 2 years ago | $37 46.36% upside | $30.5 | Benzinga | Previous targets (0) |
Unknown Leerink Partners | N/A | over 2 years ago | $48 89.87% upside | $44.16 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $53 109.65% upside | $54.73 | Benzinga | N/A |
Chris Shibutani Goldman Sachs | 25% 1/4 | over 2 years ago | $60 137.34% upside | $53.37 | Benzinga | Previous targets (3) |
Unknown Credit Suisse | N/A | almost 3 years ago | $55 117.56% upside | $48.33 | Benzinga | N/A |
David Risinger Leerink Partners | 0% 0/1 | over 3 years ago | $55 117.56% upside | $52.88 | Pulse 2.0 | Previous targets (0) |
Mohit Bansal Wells Fargo | 0% 0/3 | over 3 years ago | $141.39 459.29% upside | $49.64 | Investing | Previous targets (2) |
Mohit Bansal Wells Fargo | 0% 0/3 | over 3 years ago | $55 117.56% upside | $49.04 | TipRanks Contributor | Previous targets (2) |
Unknown Morgan Stanley | N/A | over 3 years ago | $52 105.69% upside | $49.68 | Benzinga | N/A |
Vamil Divan Mizuho Securities | 0% 0/1 | over 3 years ago | $55 117.56% upside | $49.07 | TipRanks Contributor | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 0% 0/2 | over 3 years ago | $75 196.67% upside | $53.12 | Pulse 2.0 | Previous targets (1) |
Terrance Flynn Morgan Stanley | 0% 0/1 | over 3 years ago | $55 117.56% upside | $55.17 | Pulse 2.0 | Previous targets (0) |
Andrew Baum Citigroup | 0% 0/1 | over 3 years ago | $57 125.47% upside | $55.17 | Pulse 2.0 | Previous targets (0) |
Geoff Meacham Bank of America Securities | 0% 0/1 | over 3 years ago | $70 176.89% upside | $50.27 | Pulse 2.0 | Previous targets (0) |
Carter Gould Barclays | 33.33% 1/3 | over 3 years ago | $54 113.60% upside | $51.7 | TipRanks Contributor | Previous targets (2) |
Chris Shibutani Goldman Sachs | 25% 1/4 | over 3 years ago | $50 97.78% upside | $51.7 | TipRanks Contributor | Previous targets (3) |
Chris Schott J.P. Morgan | 0% 0/1 | over 3 years ago | $57 125.47% upside | $51.7 | TipRanks Contributor | Previous targets (0) |
Evan Seigerman BMO Capital | 0% 0/2 | over 3 years ago | $76 200.63% upside | $54.95 | Pulse 2.0 | Previous targets (1) |
Aaron Gal Bernstein | 0% 0/1 | over 3 years ago | $65 157.12% upside | $56.22 | StreetInsider | Previous targets (0) |
Geoff Porges Leerink Partners | 100% 1/1 | over 3 years ago | $56 121.51% upside | $59.1 | TipRanks Contributor | Previous targets (0) |
Colin Bristow UBS | 100% 1/1 | over 3 years ago | $60 137.34% upside | $54.78 | Barrons | Previous targets (0) |
Tobias Gottschalt Independent Research | 100% 1/1 | almost 4 years ago | $54 113.60% upside | $49.8 | StreetInsider | Previous targets (0) |
Tim Anderson Wolfe Research | 100% 1/1 | almost 4 years ago | $46 81.96% upside | $44.09 | StreetInsider | Previous targets (0) |
Daniel Busby RBC Capital | 100% 1/1 | about 4 years ago | $44 74.05% upside | $42.1 | StreetInsider | Previous targets (0) |
David Toung Argus Research | 100% 1/1 | over 4 years ago | $55 117.56% upside | $37.54 | TheFly | Previous targets (0) |
Pfizer Financial Estimates
Pfizer Revenue Estimates
Pfizer EBITDA Estimates
Pfizer Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $81.28B N/A | $100.33B 23.42% | $58.49B -41.69% | Avg: $62.71B Low: $61.91B High: $64.03B avg. 7.20% | Avg: $63.29B Low: $61.16B High: $64.67B avg. 0.93% | Avg: $64.19B Low: $62.03B High: $65.59B avg. 1.42% | Avg: $62.18B Low: $60.08B High: $63.54B avg. -3.13% |
Net Income
% change YoY
| $21.97B N/A | $31.37B 42.73% | $2.11B -93.24% | Avg: $10.80B Low: $6.62B High: $16.95B avg. 410.12% | Avg: $11.64B Low: $7.93B High: $18.09B avg. 7.72% | Avg: $17.25B Low: $16.49B High: $17.74B avg. 48.16% | Avg: $16.02B Low: $15.32B High: $16.48B avg. -7.08% |
EBITDA
% change YoY
| $28.53B N/A | $43.63B 52.94% | $9.55B -78.09% | Avg: $21.10B Low: $20.84B High: $21.55B avg. 120.88% | Avg: $21.30B Low: $20.58B High: $21.77B avg. 0.93% | Avg: $21.61B Low: $20.88B High: $22.08B avg. 1.42% | Avg: $20.93B Low: $20.22B High: $21.38B avg. -3.13% |
EPS
% change YoY
| $3.95 N/A | $5.59 41.51% | $0.38 -93.20% | Avg: $1.98 Low: $1.16 High: $2.97 avg. 421.83% | Avg: $2.18 Low: $1.39 High: $3.17 avg. 9.76% | Avg: $3.02 Low: $2.89 High: $3.11 avg. 38.84% | Avg: $2.81 Low: $2.68 High: $2.89 avg. -7.08% |
Operating Expenses
% change YoY
| $30.23B N/A | $28.71B -5.02% | $25.45B -11.36% | Avg: $13.72B Low: $13.55B High: $14.01B avg. -46.06% | Avg: $13.85B Low: $13.38B High: $14.15B avg. 0.93% | Avg: $14.05B Low: $13.57B High: $14.35B avg. 1.42% | Avg: $13.61B Low: $13.15B High: $13.90B avg. -3.13% |
FAQ
What is Pfizer stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 114.73% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is 6.62B, average is 10.80B and high is 16.95B.
What is Pfizer stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1.60% in 2025-2028.
We have gathered data from 16 analysts. Their low revenue estimate is $61.91B, average is $62.71B and high is $64.03B.
What is Pfizer stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 115.83% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is $1.16, average is $1.98 and high is $2.97.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Pfizer stock. The most successful analyst is Robyn Karnauskas.